Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Die Studie zur adaptiven Plattform für chronische Nierenerkrankungen untersucht verschiedene Wirkstoffe auf ihre therapeutische Wirkung (CAPTIVATE)

29. September 2026 aktualisiert von: The George Institute

CAPTIVATE is an international, multi-centre, Phase III, adaptive, platform, randomised controlled trial in people with chronic kidney disease (CKD).

CAPTIVATE aims to find the best treatment, or combination of treatments, that slow the progression of CKD so that fewer people develop kidney failure.

CAPTIVATE provides a research platform that allows many treatment-related questions to be answered within a common trial set-up.

CAPTIVATE includes multiple domains examining different therapies for CKD. Participants may enrol in one or more domains and domains will be added and closed over time. The platform operates under a core protocol with each domain described in a domain specific appendix.

Studienübersicht

Detaillierte Beschreibung

Chronic kidney disease (CKD) affects over 800 million people globally and is projected to be the 5th most common cause of death by 2040. CKD progresses to kidney failure, increases the risk of early death, heart disease, and leads to a poorer quality of life.

Current treatments do not entirely remove the risk of kidney failure in people with CKD. To improve the outcomes of people with CKD, it is crucial to find the best treatment or combination of treatments that can slow CKD progression. CAPTIVATE aims to address this need.

CAPTIVATE has been designed to test multiple treatments within a common research platform. This design is more efficient and will lead to a shorter time for patients to receive effective treatments. The trial is 'eternal', which means that participants will continue to be recruited for many years until the trial is finally wound up. It is also 'adaptive', providing the flexibility to add new treatments, or remove those that are not working.

Participants can participate in more than one treatment at the same time or at different times. Participants receive each study treatment for 2 years. For each treatment, participants are followed up at study visits that occur at approximately one month, 3 months, 6 months, 12 months, 18 months and 2 years after starting treatment. A final study visit occurs one month after the end of the 2-year treatment phase. Information collected at study visits include blood and urine test results, safety assessments and treatment adherence. Information about the overall health status of each participant is collected every 5 years.

Studientyp

Interventionell

Einschreibung (Geschätzt)

2000

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

    • Australian Capital Territory
      • Garran, Australian Capital Territory, Australien, 2605
        • Rekrutierung
        • The Canberra Hospital
        • Kontakt:
          • Girish Talaulikar
    • New South Wales
      • Kingswood, New South Wales, Australien, 2747
        • Rekrutierung
        • Nepean Blue Mountains Local Health District
        • Kontakt:
          • Bhadran Bose
      • Kogarah, New South Wales, Australien, 2217
        • Rekrutierung
        • St George Hospital
        • Kontakt:
          • Sunil Badve
      • New Lambton Heights, New South Wales, Australien, 2305
        • Rekrutierung
        • John Hunter Hospital
        • Kontakt:
          • Bobby Chacko
      • Westmead, New South Wales, Australien, 2145
        • Rekrutierung
        • Westmead Hospital
        • Kontakt:
          • Vincent Lee
    • Queensland
      • Birtinya, Queensland, Australien, 4575
        • Rekrutierung
        • Sunshine Coast Hospital and Health Service
        • Kontakt:
          • Nicholas Gray
      • Douglas, Queensland, Australien, 4814
        • Rekrutierung
        • Townsville University Hospital
        • Kontakt:
          • Vikas Srivastava
      • Ipswich, Queensland, Australien, 4305
        • Rekrutierung
        • West Moreton Hospital & Health Service
        • Kontakt:
          • Sree Venuthurupalli
      • Southport, Queensland, Australien, 4215
        • Rekrutierung
        • Gold Coast Hospital and Health Service
        • Kontakt:
          • Jagadeesh Kurtkoti
    • South Australia
      • Adelaide, South Australia, Australien, 5000
        • Rekrutierung
        • Royal Adelaide
        • Kontakt:
          • Michael Collins
      • Elizabeth Vale, South Australia, Australien, 5112
        • Rekrutierung
        • Lyell McEwin Hospital
        • Kontakt:
          • Nitesh Rao
    • Victoria
      • Heidelberg, Victoria, Australien, 3084
        • Rekrutierung
        • Austin Health
        • Kontakt:
          • Sharon Ford
    • Western Australia
      • Murdoch, Western Australia, Australien, 6150
        • Rekrutierung
        • South Metropolitan Health Service, Fiona Stanley Hospital
        • Kontakt:
          • Suda Swaminathan
      • Dehradun, Indien, 248001
        • Noch keine Rekrutierung
        • Max Superspeciality Hospital, Dehradun
        • Kontakt:
          • Puneet Arora
      • Ghaziabad, Indien, 201012
        • Rekrutierung
        • Max Superspecialty Hospital, Ghaziabad
        • Kontakt:
          • Manoj Kumar Singhal
      • Puducherry, Indien, 607403
        • Rekrutierung
        • Aarupadai Veedu Medical College & Hospital (AVMCH), Puducherry
        • Kontakt:
          • Venkatesh A
    • Andhra Pradesh
      • Visakhapatnam, Andhra Pradesh, Indien, 530045
        • Rekrutierung
        • Gitam Institute of Medical Sciences and Research
        • Kontakt:
          • Murty Mandapaka
    • Bihar
      • Patna, Bihar, Indien, 800001
        • Rekrutierung
        • Patna Medical College and Hospital
        • Kontakt:
          • Harsh Vardhan
    • Chhattisgarh
      • Raipur, Chhattisgarh, Indien, 492002
        • Rekrutierung
        • DKS Super Speciality Hospital, Raipur
        • Kontakt:
          • Varun Agrawal
    • Dehradun
      • Dehradun, Dehradun, Indien, 248001
        • Rekrutierung
        • Mysore Medical College
        • Kontakt:
          • Puneet Arora
    • Gujarat
      • Ahmedabad, Gujarat, Indien, 380025
        • Rekrutierung
        • GCS Medical College, Hospital & Research Centre
        • Kontakt:
          • Suvika Patel
      • Vadodara, Gujarat, Indien, 390007
        • Rekrutierung
        • Aman Hospital & Research Center Vadodara
        • Kontakt:
          • Aman Khanna
    • Karnataka
      • Mangaluru, Karnataka, Indien, 575002
        • Rekrutierung
        • Father Muller Medical College Hospital
        • Kontakt:
          • Manjunath Kulkarni
    • Kerala
      • Meppādi, Kerala, Indien, 673511
        • Rekrutierung
        • Dr Moopen's Medical College
        • Kontakt:
          • Aneesh Basheer
    • Madhya Pradesh
      • Indore, Madhya Pradesh, Indien
        • Rekrutierung
        • CARE-CHL Hospital
        • Kontakt:
          • Isha Tiiwari
    • Tamil Nadu
      • Chennai, Tamil Nadu, Indien, 600024
        • Rekrutierung
        • Medway Hospital
        • Kontakt:
          • Shivakumar Dakshinamoorthy
    • Telangana
      • Hyderabad, Telangana, Indien, 500084
        • Rekrutierung
        • Yashoda Hospital Hitec City
        • Kontakt:
          • Mahesh Kota
      • Hyderabad, Telangana, Indien
        • Rekrutierung
        • Apollo Hospitals
        • Kontakt:
          • Haresh Patel
    • Uttar Pradesh
      • Lucknow, Uttar Pradesh, Indien, 226003
        • Rekrutierung
        • Charak Hospital and Research Centre
        • Kontakt:
          • Sakshi Jain
    • Uttarakhand
      • Dehradun, Uttarakhand, Indien, 248001
        • Rekrutierung
        • Shri Guru Ram Rai Medical College and Shri Mahant Indiresh Hospital
        • Kontakt:
          • Gaurav Shekhar Sharma
    • West Bengal
      • Kolkata, West Bengal, Indien, 700107
        • Rekrutierung
        • Fortis Hospital
        • Kontakt:
          • Upal Sengupta
      • Siliguri, West Bengal, Indien, 734012
        • Rekrutierung
        • North Bengal Medical College & Hospital
        • Kontakt:
          • Arpita Ray Chaudhury
      • Auckland, Neuseeland, 1023
        • Rekrutierung
        • Auckland City Hospital
        • Kontakt:
          • Dr Helen Pilmore
      • Auckland, Neuseeland, 2025
        • Rekrutierung
        • Aotearoa Clinical Trials Trust, Middlemore Hospital
        • Kontakt:
          • Kalpa Jayanatha
      • Auckland, Neuseeland, 0620
        • Rekrutierung
        • Health New Zealand, Te Whatu Ora Waitemata, North Shore Hospital
        • Kontakt:
          • Ashik Hayat
      • Dunedin, Neuseeland, 9016
        • Rekrutierung
        • 201 Great King Street, Central Dunedin, Dunedin 9016, New Zealand
        • Kontakt:
          • John Schollum
      • Palmerston North, Neuseeland, 4442
        • Rekrutierung
        • Midcentral - Palmerston North Hospital
        • Kontakt:
          • Dr Curtis Walker
      • Whangarei, Neuseeland, 0148
        • Rekrutierung
        • Private Bag 9742 Maunu Road, Horahora, Whangārei 0148, New Zealand
        • Kontakt:
          • Adam Mullan
    • Hawkes Bay
      • Hastings, Hawkes Bay, Neuseeland, 4120
        • Rekrutierung
        • Health New Zealand, Te Whatu Ora Te Matau a Maui, Hawke's Bay Hospital
        • Kontakt:
          • Hussain Allawati
    • Barcelona
      • Badalona, Barcelona, Spanien, 08916
        • Aktiv, nicht rekrutierend
        • Hospital Germans Trias i Pujol
      • Horta-Guinardó, Barcelona, Spanien, 08035
        • Rekrutierung
        • Vall d'Hebron University Hospital
        • Kontakt:
          • Dr Maria Jose Soler Romeo
    • Espana
      • Valencia, Espana, Spanien, 46010
        • Rekrutierung
        • Hospital Clinico Universitario València (INCLIVA)
        • Kontakt:
          • Prof Jose Luis Gorriz Teruel
      • Colombo, Sri Lanka, 00700
        • Rekrutierung
        • National Hospital of Sri Lanka
        • Kontakt:
          • Dr Mathu Selvarajah
      • Kandy, Sri Lanka, 20000
        • Rekrutierung
        • Kandy National Hospital
        • Kontakt:
          • Dr Nishantha Nanayakkara
      • Kurunegala, Sri Lanka
        • Rekrutierung
        • Kurunegala Teaching Hospital
        • Kontakt:
          • Dr Premil Rajakrishnan
      • Nugegoda, Sri Lanka, 10250
        • Rekrutierung
        • Sri Jayewardenepura General Hospital
        • Kontakt:
          • Dr Harshani Perera
      • Peradeniya, Sri Lanka, 20400
        • Rekrutierung
        • Peradeniya Teaching Hospital
        • Kontakt:
          • Dr Rajitha Abeysekera
      • Ragama, Sri Lanka, 11010
        • Rekrutierung
        • Colombo North Teaching Hospital
        • Kontakt:
          • Dr Nalaka Herath
    • Northern Province
      • Jaffna, Northern Province, Sri Lanka, 4000
        • Rekrutierung
        • Jaffna Teaching Hospital
        • Kontakt:
          • Dr. Brammah Thangarajah
    • Polonnaruwa
      • Colombo, Polonnaruwa, Sri Lanka, 51000
        • Rekrutierung
        • National Nephrology Specialized Hospital
        • Kontakt:
          • Dr Naseef Thaseem
    • Western Province
      • Dehiwala, Western Province, Sri Lanka, 10290
        • Rekrutierung
        • University Hospital, Kotelawala Defence University
        • Kontakt:
          • Dr Dilukshi Pilapitiya

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Age ≥ 18 years
  2. Known chronic kidney disease from any cause (eGFR ≥25 mL/min/1.73m2)
  3. Currently receiving standard of care treatment according to treating physician
  4. Eligible for randomisation in at least one recruiting domain-specific appendix
  5. Participant and treating physician are willing and able to perform trial procedures

Exclusion Criteria:

  1. Planned to commence kidney replacement therapy or kidney transplant surgery in next 6 months
  2. Life expectancy less than 6 months

To be included in any of the following DOMAINS the participant must met eligible for the PLATFORM (as listed above)

MRA domain

Inclusion Criteria:

  1. Urine albumin-creatinine ratio (uACR) >200 mg/g (22.6 mg/mmol) or urine protein-creatinine ratio (uPCR) >300 mg/g (33.9 mg/mmol) at time of screening.
  2. On a stable standard of care treatment for CKD, including a SGLT2i unless there is a documented reason not to be using a SGLT2i*, for 4 weeks before screening according to treating physician.
  3. Treating physician believes finerenone is clinically appropriate for the participant.
  4. Participant and treating physician are willing and able to perform MRA DSA procedures.
  5. Provision of written informed consent or eConsent following a fully informed discussion and prior to performing any MRA DSA related procedures

Exclusion Criteria:

  1. Recipient of kidney transplant
  2. Hyperkalaemia (serum potassium ≥5.0 mmol/L) at time of screening
  3. Current treatment with MRA, where the treating physician or patient is not willing to discontinue this medication. If willing to discontinue the MRA, the potential participant must be re-screened after they have been on stable standard of care treatment for 4 weeks without the MRA.
  4. Known allergy, intolerance or contraindication to MRAs
  5. Current treatment with strong CYP3A4 inhibitors
  6. Systolic BP <110 mmHg or diastolic BP<55 mmHg without antihypertensive therapy at time of screening
  7. Severe hepatic impairment (defined as Child-Pugh Class C)
  8. Adrenal insufficiency
  9. Currently pregnant or breast feeding, or intending to become pregnant

GLP-1 RA Domain

Inclusion Criteria

  1. Urine albumin-creatinine ratio (uACR) >200 mg/g (22.6 mg/mmol) or urine proteincreatinine ratio (uPCR) >300 mg/g (33.9 mg/mmol) at time of screening.
  2. On a stable standard of care treatment for CKD, including a SGLT2i and maximum tolerated ACEi/ARB unless there is a documented reason not to be using a SGLT2i, for 4 weeks before screening.
  3. HbA1c less than or equal to 10% (less than or equal to 86mmol/L)
  4. BMI ≥23 kg/m2 and < 50 kg/m2
  5. Treating physician believes semaglutide is clinically appropriate for the participant
  6. Participant and treating physician are willing and able to perform GLP-1 RA DSA procedures
  7. Provision of written informed consent or eConsent following a fully informed discussion and prior to performing any GLP-1 RA DSA related procedures

Exclusion Criteria

  1. Recipient of kidney transplant
  2. Major adverse cardiovascular events (MACE), consisting of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death, within 90 days prior to the day of screening
  3. Presently classified as being in New York Heart Association (NYHA) Class IV heart failure
  4. Personal or first-degree relative(s) with a history of multiple endocrine neoplasia type 2 (MEN2) or medullary thyroid carcinoma (MTC)
  5. Previous episode of pancreatitis
  6. Uncontrolled thyroid disease TSH>6.0 mIU/L or <0.4mlU/L
  7. Type 1 diabetes
  8. Current treatment with a GLP-1 RA, where it is in the participant's best interests to continue the GLP-1 RA or where the treating physician or patient is not willing to discontinue this medication for a minimum of 4 weeks prior to randomisation and for the full duration of the trial (ie. 108 weeks if assigned to placebo).
  9. Known allergy, intolerance, or contraindication to GLP-1 RAs
  10. Currently pregnant or breast feeding, or intending to become pregnant or is of child-bearing potential, and not using a highly effective contraceptive method
  11. Any disorder, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Fakultätszuweisung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Finerenone

Finerenone 10mg or 20mg tablets

Finerenone 10mg or 20mg tablets, oral, once daily

Andere Namen:
  • BAY94-8862
Placebo-Komparator: Placebo Finerenone

Finerenone matched placebo tablets

Finerenone matched placebo tablets, oral, once daily

Experimental: Semaglutide

Semaglutide 1.0 mg or 2.4 mg pen injector

Semaglutide 1.0mg or 2.4mg pen injector, subcutaneous injection, once weekly

Placebo-Komparator: Placebo Semaglutide

Semaglutide matched placebo pen injector

Semaglutide matched pen injector, subcutaneous injection, once weekly

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Core Primary Outcome Measure
Zeitfenster: From randomisation to week 108

The primary outcome is chronic eGFR slope. Chronic eGFR slope measures the rate of eGFR decline while on treatment. The duration of time over which chronic eGFR slope is computed can vary by domain and is determined by clinical considerations such as whether the investigational product can cause an acute decline in eGFR upon initiation. DSAs will specify the duration of time over which chronic eGFR slope is computed for the individual domain.

From randomisation to week 108
MRA Domain Primary Outcome Measure
Zeitfenster: From week 4 to week 108

Chronic eGFR slope estimated from all available eGFR values from week 4 to the end of treatment. The final eGFR value that contributes to the primary outcome is the last eGFR measured while the participant is on treatment.

From week 4 to week 108
GLP1-RA Domain Primary Outcome Measure
Zeitfenster: From week 0 to week 108

Chronic eGFR slope estimated from all available eGFR values from Week 0 to the end of treatment. The final eGFR value that contributes to the primary outcome is the last eGFR measured while the participant is on treatment.

From week 0 to week 108

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Core Protocol Secondary outcomes
Zeitfenster: week 0 and 24 weeks

1. Change in albuminuria as measured by uACR (or uPCR if uACR unavailable) between week 0 and 24 weeks, measured as a continuous variable.

week 0 and 24 weeks
Core Protocol Secondary outcomes
Zeitfenster: week 0 to end of washout

2. eGFR slope from week 0 to end of washout

week 0 to end of washout
Core Protocol Secondary outcomes
Zeitfenster: week 0 to end of washout

3. Change in eGFR from week 0 to end of washout

week 0 to end of washout
Core Protocol Secondary outcomes
Zeitfenster: between week 0 and 108 weeks

4. Composite outcome of proportion of participants experiencing a ≥40% eGFR decline between week 0 and 108 weeks, and proportion of participants developing kidney failure (defined as eGFR <15 mL/min/1.73m2 or chronic kidney replacement therapy start†) at 108 weeks.

between week 0 and 108 weeks
Core Protocol Secondary outcomes
Zeitfenster: from start of study drug (week 0) to washout (week 108) or kidney failure

5. Time to a composite outcome of ≥40% eGFR decline from week 0 or kidney failure

from start of study drug (week 0) to washout (week 108) or kidney failure
Core Protocol Secondary outcomes
Zeitfenster: at 108 weeks

6. All-cause mortality at 108 weeks

at 108 weeks
Core Protocol Secondary outcomes
Zeitfenster: between week 0 and week 108

7. Proportion of participants experiencing one or more cardiovascular events (cardiovascular death, hospitalised heart failure, myocardial infarction, stroke)* between week 0 and week 108

between week 0 and week 108
Core Protocol Secondary outcomes
Zeitfenster: from start of study drug (week 0) to end of washout (week 108)

8. Time to first occurrence of a cardiovascular event

from start of study drug (week 0) to end of washout (week 108)
Core Protocol Secondary outcomes
Zeitfenster: from start of study drug (week 0) to end of treatment (up to week 104)

9. Safety and tolerability of treatment

from start of study drug (week 0) to end of treatment (up to week 104)
Core Protocol Secondary outcomes
Zeitfenster: 6-monthly intervals from randomisation to week 108

10. Change in quality of life measured using the Quality of Life Impact Survey for Kidney Disease (QDISCKD) at 6-monthly intervals from randomisation to week 108.

6-monthly intervals from randomisation to week 108
MRA Domain Secondary Outcome
Zeitfenster: from start of study drug (week 0) to end of washout (week 108)

MRA DSA has a domain-specific secondary outcome that evaluates the time to the composite of ≥57% eGFR decline from week 0 or kidney failure

from start of study drug (week 0) to end of washout (week 108)
GLP-1 RA Domain Secondary Outcome
Zeitfenster: from start of study drug (week 0) to end of washout (week 108)

1. Change in eGFR slope from Week 0 to Week 108.

from start of study drug (week 0) to end of washout (week 108)
GLP-1 RA Domain Secondary Outcome
Zeitfenster: from start of study drug (week 0) to end of washout (week 108)

2. Time to composite of onset of kidney failure (initiation of long-term dialysis, kidney transplantation, or a reduction in the eGFR to <15 mL per minute per 1.73 m2 sustained for ≥28 days), a sustained (for ≥28 days) 50% or greater reduction in eGFR from Week 0, or death from kidney-related or cardiovascular causes.

from start of study drug (week 0) to end of washout (week 108)
GLP-1 RA Domain Secondary Outcome
Zeitfenster: from Week 0 to Week 108

3. Time to first occurrence of onset of persistent ≥50% reduction in eGFR from Week 0 to Week 108

from Week 0 to Week 108
GLP-1 RA Domain Secondary Outcome
Zeitfenster: from start of study drug (week 0) to end of washout (week 108)

4. Time to first occurrence of a composite outcome of major adverse cardiovascular events (MACE) consisting of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death

from start of study drug (week 0) to end of washout (week 108)
GLP-1 RA Domain Secondary Outcome
Zeitfenster: from start of study drug (week 0) to end of washout (week 108)

5. Time to occurrence of all-cause death

from start of study drug (week 0) to end of washout (week 108)
GLP-1 RA Domain Secondary Outcome
Zeitfenster: from Week 0 to Week 108

6. Change in body weight from Week 0 to Week 108

from Week 0 to Week 108
GLP-1 RA Domain Secondary Outcome
Zeitfenster: Week 0 to Week 108

7. Change in HbA1c from Week 0 to Week 108

Week 0 to Week 108
GLP-1 RA Domain Secondary Outcome
Zeitfenster: from Week 0 to Week 108

8. Change in systolic blood/diastolic blood pressure from Week 0 to Week 108

from Week 0 to Week 108
GLP-1 RA Domain Secondary Outcome
Zeitfenster: from Week 0 to Week 108

9. Change in NT-proBNP from Week 0 to Week 108

from Week 0 to Week 108
GLP-1 RA Domain Secondary Outcome
Zeitfenster: from randomisation to Week 108

10. Change in health status measured using the 23-item Kansas City Cardiomyopathy Questionnaire (KCCQ) at 6-monthly intervals from randomisation to Week 108

from randomisation to Week 108
GLP-1 RA Domain Secondary Outcome
Zeitfenster: Week 0 to end of trial

11. Incidence of AEs and the following medical events of special interest (MESI) from Week 0 to end of trial:

  1. Neoplasm (malignant and benign)
  2. Pancreatitis, or persistent abdominal pain leading to a suspicion of pancreatitis
  3. Acute gallstone disease (biliary colic or acute cholecystitis)
  4. Thyroid disease
  5. Cardiac arrhythmia (specifically, atrial fibrillation, atrial flutter, ventricular tachycardia, ventricular fibrillation, torsade de pointes, second degree heart block type 2, third degree heart block, and symptomatic bradycardia requiring pacemaker placement)
  6. Severe hypoglycaemic episodes
  7. Immunogenicity events (allergic reactions, immune-complex disease, and lack of efficacy)
  8. Adverse events leading to treatment discontinuation (if not any of the mentioned MESIs)
  9. Ocular adverse events
  10. Suspicion of transmission of infectious agents
Week 0 to end of trial

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Studienstuhl: Sradha Kotwal, The George Institute
  • Studienstuhl: Hiddo Lambers Heerspink, The George Institute

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

4. September 2024

Primärer Abschluss (Geschätzt)

31. Dezember 2029

Studienabschluss (Geschätzt)

31. Dezember 2029

Studienanmeldedaten

Zuerst eingereicht

21. September 2023

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

21. September 2023

Zuerst gepostet (Tatsächlich)

28. September 2023

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

5. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

29. September 2026

Zuletzt verifiziert

1. August 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

Trial data will be made available as a resource for future unspecified research, subject to any prior contractual obligations. Researchers wishing to gain access to the study resources will be required to submit an application for review by the Platform Oversight Committee, including a detailed project description, a list of data requested, and evidence of ethical approval. De-identified data extracts will be made available to approved proposals, and will not include data obtained from data linkage with local registries.

IPD-Sharing-Zeitrahmen

TBC

IPD-Sharing-Zugriffskriterien

Assessments of data requests will be based on sound science, benefit-risk balancing and research team expertise.

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • SAFT
  • ICF
  • CSR

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren